Alumis
Tim Owens is a seasoned professional in the pharmaceutical industry, currently serving as Sr Vice President at Alumis since May 2022. Previously, Tim held the position of Head of Research at Principia Biopharma, a Sanofi Company, from February 2021 to April 2022, and has enjoyed a long tenure at the same organization in various leadership roles, including Vice President, Director of Medicinal Chemistry, and Associate Director from December 2011 to February 2021. Earlier experience includes working as a Senior Scientist at Roche-Nutley and as a Research Scientist at Roche-Palo Alto. Tim began a postdoctoral fellowship at Memorial Sloan-Kettering Cancer Center from 2002 to 2004 and started a career in research as a Research Associate at Corvas, Intl from 1995 to 1997. Tim holds a PhD in Chemistry from the University of California, Berkeley, and a BS in Chemistry/Biochemistry from UC San Diego.
Alumis
2 followers
At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.